PIC Therapeutics

📍 Natick, United States🗓 Founded 2016👥 11 employees💰 Last funded Sep 2016
Biotechnology Research🌐 pictherapeutics.com
Website LinkedIn
PIC Therapeutics is a biotechnology company focused on fundamentally changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation. PIC Therapeutics was founded on the seminal work of Dr. Gerhard Wagner, a professor at Harvard Medical School world-renowned for his scientific expertise in protein structure and his research on interactions of eukaryotic translation initiation factors (eIFs). PIC Therapeutics, led by President and CEO Dr. Kathy Bowdish, was launched to translate these discoveries into small molecule precision therapeutics to benefit cancer patients. Our precision-based therapeutics target the “master switch” of cancer signaling pathways, selectively blocking oncogene protein production by modulating the Pre-Initiation Complex (PIC) that drives their mRNA translation. Our selective approach has the potential to simultaneously modulate multiple oncogenic drivers leading to a powerful new generation of cancer-treating therapeutics.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in PIC Therapeutics?
PIC Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did PIC Therapeutics last raise funding?
The most recent investment in PIC Therapeutics recorded on gritt.io was in September 2016.
When was PIC Therapeutics founded?
PIC Therapeutics was founded in 2016.
What industry is PIC Therapeutics in?
PIC Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is PIC Therapeutics based?
PIC Therapeutics is headquartered in Natick, United States.